Janssen’s Xarelto Earns FDA Approval for Preventing Blood Clots

The FDA approved Janssen Pharmaceuticals’ Xarelto (rivaroxaban) to prevent blood clots in acutely ill patients and following their hospital discharge.

Under the new indication, Xarelto can be initiated for acutely ill patients during hospitalization and continued after discharge for a recommended duration of 31 to 99 days.

The FDA has granted Xarelto eight indications to date, including six for the treatment, prevention and reduction in the risk of recurrence of blood clots across a wide range of patient populations.